Acuitive Technologies received FDA clearance for Citrepore, a synthetic bioactive bone filler designed to promote natural bone healing in orthopedic surgery patients. Citrepore has 80% porosity to allow resorption of saline, blood, and bone marrow aspirate. The filler is osteoconductive and bioactive, promoting bone healing by increasing genetic signaling for metabolism, osteoinduction, osteoconduction, and extracellular matrix production in response to citrate. This FDA clearance expands treatment options for patients undergoing orthopedic procedures and highlights the potential of Citrepore in enhancing bone healing outcomes.
Source link
Acuitive Technologies receives FDA 510(k) clearance of bioactive bone void filler
